Wednesday, December 26, 2012

Otsuka receives regulatory approval for L-Cartin FF oral solutionand FF injection (1000mg) for treatment of carnitine deficiency

Otsuka Pharmaceutical Co., Ltd. has received regulatory approvals today for L-Cartin FF oral solution and L-Cartin FF injection 1000mg, indicated for carnitine deficiency.
  • Oral solution was developed to ease the patients having difficulties taking the carnitine tablets, and the injection form was developed for carnitine deficient patients who require immediate supplementation of carnitine, or for those unable to orally intake carnitine.
  • Carnitine deficiency can be found in patients with inborn error of metabolism and in hemodialysis patients for example, through symptoms such as muscle pains, or even hypoglycemic coma in severe cases.

Enter your email address:


Delivered by FeedBurner